ストックスクリーナーアプリを入手
32.09
0.42%
0.075
前日終値:
$32.02
開ける：
$32.1
24時間の取引高:
19,439
Relative Volume:
0.05
時価総額：
$1.80B
収益：
$345.60M
当期純損益:
$-79.01M
株価収益率:
-20.00
EPS:
-1.6045
ネットキャッシュフロー:
$-18.62M
1週間 パフォーマンス:
+2.60%
1か月 パフォーマンス:
+0.36%
6か月 パフォーマンス:
+10.20%
1年 パフォーマンス:
-4.81%
1日の値動き範囲:
$31.95
$32.49
1週間の範囲:
$30.80
$32.55
52週間の値動き範囲:
$23.15
$41.54
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
名前
Immunocore Holdings Plc Adr
セクター
電話
01235 5430281
住所
90 PARK DRIVE, OXFORDSHIRE
IMCR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
32.10 | 1.80B | 345.60M | -79.01M | -18.62M | -1.6045 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.77 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.50 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
316.63 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.29 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
243.24 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-27 | 開始されました | Deutsche Bank | Buy |
| 2024-12-13 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-11-11 | ダウングレード | Mizuho | Outperform → Neutral |
| 2024-10-24 | 開始されました | UBS | Sell |
| 2024-10-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-04-29 | 開始されました | Leerink Partners | Outperform |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-11-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-31 | 開始されました | Robert W. Baird | Outperform |
| 2023-09-13 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-09-13 | 開始されました | Needham | Buy |
| 2023-08-16 | 開始されました | CapitalOne | Overweight |
| 2023-07-17 | 開始されました | Canaccord Genuity | Hold |
| 2023-03-31 | 開始されました | Mizuho | Buy |
| 2023-03-30 | 開始されました | Guggenheim | Buy |
| 2023-03-24 | 開始されました | Bryan Garnier | Buy |
| 2022-12-16 | アップグレード | Goldman | Neutral → Buy |
| 2022-11-30 | 開始されました | Barclays | Overweight |
| 2022-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2022-09-08 | 開始されました | Ladenburg Thalmann | Buy |
| 2022-08-08 | 開始されました | Cowen | Outperform |
| 2022-08-02 | 開始されました | BTIG Research | Buy |
| 2022-02-08 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-20 | 開始されました | Oppenheimer | Outperform |
| 2021-03-02 | 開始されました | Goldman | Neutral |
| 2021-03-02 | 開始されました | JP Morgan | Overweight |
| 2021-03-02 | 開始されました | Jefferies | Buy |
すべてを表示
Immunocore Holdings Plc Adr (IMCR) 最新ニュース
Immunocore’s SWOT analysis: stock outlook amid pipeline progress, market challenges By Investing.com - Investing.com South Africa
Immunocore’s SWOT analysis: stock outlook amid pipeline progress, market challenges - Investing.com India
Immunocore at Jefferies Global Healthcare Conference: Strong Growth and Promising Trials - Investing.com India
Wall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a Bet - sharewise
Deutsche Bank sets $65 target on Immunocore stock, rates Buy - Investing.com
Deutsche Bank sets $65 target on Immunocore stock, rates Buy By Investing.com - Investing.com India
Immunocore’s SWOT analysis: biotech firm’s stock faces challenges amid growth - Investing.com India
Is it a Good Idea to Invest in Immunocore Stock Right Now? - MSN
Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - MSN
Balance Sheet Dive: Hippo Holdings Inc (HIPO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Analyzing Ratios: Symbotic Inc (SYM)’s Financial Story Unveiled - DWinneX
New Strong Buy Stocks for May 8th - The Globe and Mail
Immunocore stock rises as Q1 results top estimates By Investing.com - Investing.com South Africa
Immunocore stock rises as Q1 results top estimates - Investing.com
Immunocore Holdings earnings beat by $0.49, revenue topped estimates - Investing.com
Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down - Barchart.com
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y - The Globe and Mail
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates - Barchart.com
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y - Barchart.com
Wall Street Analysts Think Immunocore (IMCR) Could Surge 107.45%: Read This Before Placing a Bet - Yahoo Finance
Mizuho cuts Immunocore stock price target to $33 from $38 - Investing.com
Immunocore stock hits 52-week low at $27.19 amid market challenges By Investing.com - Investing.com South Africa
Immunocore stock hits 52-week low at $27.19 amid market challenges - Investing.com
Do investors need to be concerned about Immunocore Holdings plc ADR (IMCR)? - US Post News
Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last? - MSN
Immunocore holdings sees $23.99 million in stock purchases by Baker Bros - Investing.com South Africa
Immunocore amends senior notes indenture, files prospectus - Investing.com India
Immunocore amends senior notes indenture, files prospectus By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $100 target on Immunocore stock - Investing.com
Immunocore’s SWOT analysis: biotech firm’s stock outlook amid HIV and cancer drug progress - Investing.com
BTIG maintains Immunocore stock Buy rating, $91 target - Investing.com
Immunocore stock hits 52-week low at $27.59 amid market challenges - Investing.com
Immunocore reports promising HIV trial results By Investing.com - Investing.com South Africa
Immunocore reports promising HIV trial results - Investing.com India
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 - GlobeNewswire Inc.
Immunocore at TD Cowen Conference: Strategic Growth and Innovation - Investing.com India
Immunocore at TD Cowen Conference: Strategic Growth and Innovation By Investing.com - Investing.com South Africa
PBYI Stock Rises as Q4 Earnings & Sales Outpace EstimatesFebruary 28, 2025 - Zacks Investment Research
Earnings call transcript: Immunocore Holdings Q4 2024 misses EPS - Investing.com
Immunocore Holdings Plc Adr (IMCR) 財務データ
収益
当期純利益
現金流量
EPS
1.37%
0.65%
大文字化:
|
ボリューム (24 時間):